Four trials go to human phase!

Alzheimer; News from the web:

Ionis and Biogen are bringing to bear the Ionis drug technology called antisense, which targets diseases processes at the genetic level. It blocks or modifies production of proteins involved in disease.

The Phase 1/2a study of the Alzheimer’s drug, IONIS-MAPTRx, seeks evidence of safety and signs of activity. It’s to be given in 44 patients with mild Alzheimer’s over three months.The drug targets microtubule-associated tau protein, also called MATP, or tau, an abnormal protein associated with Alzheimer’s.

Read all about it HERE

Alzheimer’s is a young or middle-aged person’s disease

Alzheimer; News from the web:

“Alzheimer’s disease starts in the brain more than twenty years before the first symptom,” said Richard Isaacson, director of the Alzheimer’s Prevention Clinic at New York-Presbyterian/Weill-Cornell Medical Center. “Alzheimer’s disease is not an older person’s disease. It’s a disease of younger and middle-aged people. And that’s how we have to shift the paradigm.”

Read all about it HERE